Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7034MR)

This product GTTS-WQ7034MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7034MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15798MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ10927MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MABT5102A
GTTS-WQ5995MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ15628MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ1525MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ865MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ15591MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ7103MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW